Combining prognostic value of serum carbohydrate antigen 19-9 and tumor size reduction ratio in pancreatic ductal adenocarcinoma

Figure 1 Kaplan-Meier curves for patients according to carbohydrate antigen 19-9. A and B: Kaplan-Meier curves for overall survival (A) and disease-free survival (B) are presented for post-neoadjuvant therapy (NAT) serum carbohydrate antigen 19-9 (CA19-9) level/pre-NAT serum CA19-9 level, which was defined as the carbohydrate antigen 19-9 ratio (CR).